Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 9Urinary Bladder Neoplasms 1Resectable HER2-positive Breast Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplastic Cells, Circulating 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1HR-positive,HER2-negative Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-negative Early Breast Cancer 1HER2-negative Breast Cancer 1HER2 Positive Early Breast Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Adenoid Cystic 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × Epirubicin × Clear all
NCT06421948 2025-12-05

Linperlisib Combined With Chidamide in Patients With PTCL

Henan Cancer Hospital

Phase 1/2 Recruiting
134 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡